|Day Low/High||0.02 / 0.02|
|52 Wk Low/High||0.01 / 12.80|
Drops in Achaogen and Sophiris Bio offered the chance to use an options strategy known as buy-write.
Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.
Your questions are answered in our latest addition of the biotech mailbag.
These equities are showing technical characteristics of bullish and bearish reversal patterns.
Several biotech names held up well or even had solid advances during last week's broad market selloff.
Real Money stock picks from Tim Collins, Skip Raschke, Jim Collins and Bret Jensen.
Achaogen, Taylor Morrison and Synchrony Financial are a part of my current shopping list.
I've added to my positions in these names on yesterday's intraday silliness.
The Summit, N.J.-based firm on Oct. 26 unveiled third-quarter results and updated its 2017 outlook and financial targets for 2020.
Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.
Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.
If the indices take out yesterday's lows I'll be very bearish very quickly.
Sometimes you just have to be patient and let the market come to you rather than force questionable entries.
There is no fundamental reason for DJIA volume to suddenly double and continue at that level.